Are you concerned that your rheumatoid arthritis (RA) medications might cause cancer? You’re not alone. This fear is common—but separating fact from fear is critical for making informed decisions about your health.
Dr. Siddharth Tambar from Chicago Arthritis and Regenerative Medicine explains the real risks and the role of these medications in effectively treating RA.
Understanding RA and Why Medication Matters
RA is an autoimmune disease where the immune system attacks healthy joints, leading to pain, inflammation, and long-term joint damage. If untreated, RA can cause deformities, disability, heart disease, and even shorten lifespan. Early and effective treatment is essential—not only for symptom relief but for long-term health preservation.
What Are RA Medications?
RA treatments include DMARDs (disease-modifying anti-rheumatic drugs), which slow or stop the disease process. Common types include:
-
Methotrexate (traditional DMARD)
-
Biologics (e.g., Humira, Enbrel)
-
JAK inhibitors (e.g., Xeljanz, Rinvoq)
These are not just symptom relievers; they target the immune system to prevent ongoing joint damage.
Methotrexate and Cancer Risk
Methotrexate, the most widely used RA medication, is sometimes confused with chemotherapy. However, for RA, it’s used in much lower doses and acts as an immune modulator.
Research shows methotrexate does not increase the risk of most cancers, with a possible slight increase in lymphoma. However, this risk is hard to separate from the effects of chronic RA inflammation itself.
Biologics: Powerful but Safe?
Biologics have transformed RA care, offering many patients remission-level relief. They target specific immune pathways but also raise concerns about cancer due to their immunosuppressive nature.
Large studies show no significant increase in overall cancer risk from biologics. However, there’s a slightly higher risk of non-melanoma skin cancers, so regular skin checks are advised—especially for those with prior skin cancer history.
JAK Inhibitors and Higher-Risk Groups
JAK inhibitors are newer and act deep within immune cells. A 2021 study found a slightly higher risk of cancer (especially lung cancer and lymphoma) in older adults with heart disease risk factors, particularly smokers.
But for younger, healthy, non-smokers, cancer risk with JAK inhibitors is still considered low.
The Bigger Risk? Untreated RA
A little-known fact: RA itself can increase cancer risk—especially lymphoma—due to chronic inflammation. Skipping medication out of fear may actually raise your cancer risk more than taking it.
Personalized, Monitored, and Safe Treatment
Dr. Tambar emphasizes a personalized approach:
-
Start with lower-risk meds (methotrexate or hydroxychloroquine)
-
Escalate only if necessary
-
Tailor treatment based on age, smoking status, and health history
-
Use shared decision-making with patients
-
Incorporate lifestyle changes (anti-inflammatory diet, exercise, stress reduction, no smoking)
Common Patient Questions
-
Is methotrexate dangerous because it’s used in cancer?
No—the RA dosage is 100x lower and much safer. -
Do I have to take medication forever?
Not always. Tapering is possible if RA is well controlled. -
Should I get more cancer screenings?
Standard screenings are enough unless you’re at higher risk (e.g., smoker). -
Can I treat RA naturally?
Lifestyle helps—but cannot replace medications for moderate to severe RA.
Final Takeaway
The cancer risk from RA medications is generally low and far outweighed by the dangers of untreated RA. Work with your physician to find the safest, most effective plan for your health.
Methotrexate for Rheumatoid Arthritis: Dosage, Effects, and When to Switch to Biologics
Biologics for Rheumatoid Arthritis: Risks, Benefits & What You Need to Know